Scott M. Haake
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Scott M. Haake has a total of 164 co-authors. Here are the top co-authors by number of shared publications:
- Brian I. Rini
Vanderbilt Ingram Cancer Center, Nashville, TN, USA
6 shared publications W. Kimryn Rathmell
Department of Medicine, Vanderbilt University Medical Center, Nashville, USA
6 shared publications- Kathryn E. Beckermann
Medical Director of GU Clinical Research, Greco-Hainsworth Center for Research, Tennessee Oncology , Nashville, TN 37203
5 shared publications - W. Kimryn Rathmell
Department of Medicine, Vanderbilt University Medical Center, Nashville, USA
5 shared publications - Jeffrey C. Rathmell
Department of Pathology, Microbiology and Immunology, Molecular Pathogenesis Division, Vanderbilt University Medical Center
4 shared publications - Emily N. Arner
Department of Medicine, Vanderbilt University Medical Center, Nashville, USA
3 shared publications
Latest Publications
- Open Access
- 23 October 2026
- Published by Springer Nature in npj Precision Oncology
An individual sample predictive model to classify patients with metastatic renal cell carcinoma
- 23 October 2026
- Published by Springer Nature in npj Precision Oncology
Open AccessAn individual sample predictive model to classify patients with metastatic renal cell carcinoma
- Open Access
Not All Predictors Of RCC Clusters Are The Same: An individual sample predictive model to classify patients with metastatic renal cell carcinoma
Clear cell renal cell carcinoma (RCC) patients have multiple approved therapies, including anti-angiogenesis tyrosine kinase inhibitors (TKIs) and immuno-oncology therapies (IO), but lack a clinically validated biomarker. Using RNAseq data from the IMmotion 151 clinical trial (IM151) 1–3 , 7 RCC biologic clusters have been defined 3 . Several groups have attempted to predict these clusters on various RCC datasets 4,5 with negative results, suggesting that the association with therapy response from IM151 could not be reproduced. We hypothesized that the specific approaches used to generate cluster predictions led to the misinterpretation of findings. Both published models used standardization (z-scores) to normalize the data within their patient cohorts, imposing an expected gene expression distribution in which ∼50% of patients have apparently higher-than-average expression, artificially impacting the proportion of cluster assignments and leading to potential misclassification. We developed a machine learning (ML) model, IRIS-RCC (Individual RNA-seq Intrinsic Subtyping for RCC), to predict treatment (TKI vs. IO) for patients using an individual-sample model using the IM151 trial (N=823) and validated the model on the JAVELIN Renal 101 trial (JR101; N=726) 3,6 . Our method normalizes gene expression within a given sample using ratiometric expression. This method results in different cluster assignments for individual tumors and distinct clinical correlations. An additional advantage of individual-sample predictions is that they can be readily applied in a prospective setting, where patients must be classified one at a time. IRIS-RCC is currently being validated in a prospective biomarker-driven Phase II clinical trial (OPTIC RCC).
Open AccessNot All Predictors Of RCC Clusters Are The Same: An individual sample predictive model to classify patients with metastatic renal cell carcinoma
Clear cell renal cell carcinoma (RCC) patients have multiple approved therapies, including anti-angiogenesis tyrosine kinase inhibitors (TKIs) and immuno-oncology therapies (IO), but lack a clinically validated biomarker. Using RNAseq data from the IMmotion 151 clinical trial (IM151) 1–3 , 7 RCC biologic clusters have been defined 3 . Several groups have attempted to predict these clusters on various RCC datasets 4,5 with negative results, suggesting that the association with therapy response from IM151 could not be reproduced. We hypothesized that the specific approaches used to generate cluster predictions led to the misinterpretation of findings. Both published models used standardization (z-scores) to normalize the data within their patient cohorts, imposing an expected gene expression distribution in which ∼50% of patients have apparently higher-than-average expression, artificially impacting the proportion of cluster assignments and leading to potential misclassification. We developed a machine learning (ML) model, IRIS-RCC (Individual RNA-seq Intrinsic Subtyping for RCC), to predict treatment (TKI vs. IO) for patients using an individual-sample model using the IM151 trial (N=823) and validated the model on the JAVELIN Renal 101 trial (JR101; N=726) 3,6 . Our method normalizes gene expression within a given sample using ratiometric expression. This method results in different cluster assignments for individual tumors and distinct clinical correlations. An additional advantage of individual-sample predictions is that they can be readily applied in a prospective setting, where patients must be classified one at a time. IRIS-RCC is currently being validated in a prospective biomarker-driven Phase II clinical trial (OPTIC RCC).
- 16 April 2025
- Published by Springer Nature in Nature Cancer
- Vol. 6 (4) , 573-583
Biomarker-informed care for patients with renal cell carcinoma
Kidney cancer is a commonly diagnosed cancer in adults, and clear cell renal cell carcinoma (ccRCC) is the most common histological subtype. Immune checkpoint inhibitors have revolutionized care for patients with ccRCC, either as adjuvant therapy or combined with other agents in advanced disease. However, biomarkers to predict therapeutic benefits are lacking. Here, we explore biomarkers that predict therapeutic response in other tumor types and discuss the reasons for their ineffectiveness in ccRCC. We also review emerging predictive and prognostic biomarkers to prioritize in ccRCC, including gene expression signatures.
- 16 April 2025
- Published by Springer Nature in Nature Cancer
- Vol. 6 (4) , 573-583
Biomarker-informed care for patients with renal cell carcinoma
Kidney cancer is a commonly diagnosed cancer in adults, and clear cell renal cell carcinoma (ccRCC) is the most common histological subtype. Immune checkpoint inhibitors have revolutionized care for patients with ccRCC, either as adjuvant therapy or combined with other agents in advanced disease. However, biomarkers to predict therapeutic benefits are lacking. Here, we explore biomarkers that predict therapeutic response in other tumor types and discuss the reasons for their ineffectiveness in ccRCC. We also review emerging predictive and prognostic biomarkers to prioritize in ccRCC, including gene expression signatures.
- 26 September 2024
- Published by Elsevier in European Urology
- Vol. 87 (1) , 84-85
Refining the Tissue Source for Biomarker-based Approaches in Renal Cell Carcinoma
- 26 September 2024
- Published by Elsevier in European Urology
- Vol. 87 (1) , 84-85
Refining the Tissue Source for Biomarker-based Approaches in Renal Cell Carcinoma
- Open Access
- 9 July 2024
- Published by Springer Nature in Nature
- Vol. 631 (8022) , E16
Author Correction: Obesity induces PD-1 on macrophages to suppress anti-tumour immunity
- 9 July 2024
- Published by Springer Nature in Nature
- Vol. 631 (8022) , E16
Open AccessAuthor Correction: Obesity induces PD-1 on macrophages to suppress anti-tumour immunity
- Top Cited Papers
- 12 June 2024
- Published by Springer Nature in Nature
- Vol. 630 (8018) , 968-975
Obesity induces PD-1 on macrophages to suppress anti-tumour immunity
Obesity is a leading risk factor for progression and metastasis of many cancers1,2, yet can in some cases enhance survival3,4,5 and responses to immune checkpoint blockade therapies, including anti-PD-1, which targets PD-1 (encoded by PDCD1), an inhibitory receptor expressed on immune cells6,7,8. Although obesity promotes chronic inflammation, the role of the immune system in the obesity–cancer connection and immunotherapy remains unclear. It has been shown that in addition to T cells, macrophages can express PD-19,10,11,12. Here we found that obesity selectively induced PD-1 expression on tumour-associated macrophages (TAMs). Type I inflammatory cytokines and molecules linked to obesity, including interferon-γ, tumour necrosis factor, leptin, insulin and palmitate, induced macrophage PD-1 expression in an mTORC1- and glycolysis-dependent manner. PD-1 then provided negative feedback to TAMs that suppressed glycolysis, phagocytosis and T cell stimulatory potential. Conversely, PD-1 blockade increased the level of macrophage glycolysis, which was essential for PD-1 inhibition to augment TAM expression of CD86 and major histocompatibility complex I and II molecules and ability to activate T cells. Myeloid-specific PD-1 deficiency slowed tumour growth, enhanced TAM glycolysis and antigen-presentation capability, and led to increased CD8+ T cell activity with a reduced level of markers of exhaustion. These findings show that obesity-associated metabolic signalling and inflammatory cues cause TAMs to induce PD-1 expression, which then drives a TAM-specific feedback mechanism that impairs tumour immune surveillance. This may contribute to increased cancer risk yet improved response to PD-1 immunotherapy in obesity.
- 12 June 2024
- Published by Springer Nature in Nature
- Vol. 630 (8018) , 968-975
Top Cited PapersObesity induces PD-1 on macrophages to suppress anti-tumour immunity
Obesity is a leading risk factor for progression and metastasis of many cancers1,2, yet can in some cases enhance survival3,4,5 and responses to immune checkpoint blockade therapies, including anti-PD-1, which targets PD-1 (encoded by PDCD1), an inhibitory receptor expressed on immune cells6,7,8. Although obesity promotes chronic inflammation, the role of the immune system in the obesity–cancer connection and immunotherapy remains unclear. It has been shown that in addition to T cells, macrophages can express PD-19,10,11,12. Here we found that obesity selectively induced PD-1 expression on tumour-associated macrophages (TAMs). Type I inflammatory cytokines and molecules linked to obesity, including interferon-γ, tumour necrosis factor, leptin, insulin and palmitate, induced macrophage PD-1 expression in an mTORC1- and glycolysis-dependent manner. PD-1 then provided negative feedback to TAMs that suppressed glycolysis, phagocytosis and T cell stimulatory potential. Conversely, PD-1 blockade increased the level of macrophage glycolysis, which was essential for PD-1 inhibition to augment TAM expression of CD86 and major histocompatibility complex I and II molecules and ability to activate T cells. Myeloid-specific PD-1 deficiency slowed tumour growth, enhanced TAM glycolysis and antigen-presentation capability, and led to increased CD8+ T cell activity with a reduced level of markers of exhaustion. These findings show that obesity-associated metabolic signalling and inflammatory cues cause TAMs to induce PD-1 expression, which then drives a TAM-specific feedback mechanism that impairs tumour immune surveillance. This may contribute to increased cancer risk yet improved response to PD-1 immunotherapy in obesity.
- Open Access
- 25 April 2024
- Published by Elsevier in Matrix Biology
- Vol. 130, 20-35
Integrating integrins with the hallmarks of cancer
- 25 April 2024
- Published by Elsevier in Matrix Biology
- Vol. 130, 20-35
Open AccessIntegrating integrins with the hallmarks of cancer
- Open Access
- 5 March 2024
- Published by American Society for Clinical Investigation in Journal of Clinical Investigation
- Vol. 134 (8)
VHL loss reprograms the immune landscape to promote an inflammatory myeloid microenvironment in renal tumorigenesis
Clear cell renal cell carcinoma (ccRCC) is characterized by dysregulated hypoxia signaling and a tumor microenvironment (TME) highly enriched in myeloid and lymphoid cells. Loss of the von Hippel Lindau ( VHL ) gene is a critical early event in ccRCC pathogenesis and promotes stabilization of HIF. Whether VHL loss in cancer cells affects immune cells in the TME remains unclear. Using Vhl WT and Vhl -KO in vivo murine kidney cancer Renca models, we found that Vhl- KO tumors were more infiltrated by immune cells. Tumor-associated macrophages (TAMs) from Vhl- deficient tumors demonstrated enhanced in vivo glucose consumption, phagocytosis, and inflammatory transcriptional signatures, whereas lymphocytes from Vhl- KO tumors showed reduced activation and a lower response to anti–programmed cell death 1 (anti–PD-1) therapy in vivo. The chemokine CX3CL1 was highly expressed in human ccRCC tumors and was associated with Vhl deficiency. Deletion of Cx3cl1 in cancer cells decreased myeloid cell infiltration associated with Vhl loss to provide a mechanism by which Vhl loss may have contributed to the altered immune landscape. Here, we identify cancer cell–specific genetic features that drove environmental reprogramming and shaped the tumor immune landscape, with therapeutic implications for the treatment of ccRCC.
- 5 March 2024
- Published by American Society for Clinical Investigation in Journal of Clinical Investigation
- Vol. 134 (8)
Open AccessVHL loss reprograms the immune landscape to promote an inflammatory myeloid microenvironment in renal tumorigenesis
Clear cell renal cell carcinoma (ccRCC) is characterized by dysregulated hypoxia signaling and a tumor microenvironment (TME) highly enriched in myeloid and lymphoid cells. Loss of the von Hippel Lindau ( VHL ) gene is a critical early event in ccRCC pathogenesis and promotes stabilization of HIF. Whether VHL loss in cancer cells affects immune cells in the TME remains unclear. Using Vhl WT and Vhl -KO in vivo murine kidney cancer Renca models, we found that Vhl- KO tumors were more infiltrated by immune cells. Tumor-associated macrophages (TAMs) from Vhl- deficient tumors demonstrated enhanced in vivo glucose consumption, phagocytosis, and inflammatory transcriptional signatures, whereas lymphocytes from Vhl- KO tumors showed reduced activation and a lower response to anti–programmed cell death 1 (anti–PD-1) therapy in vivo. The chemokine CX3CL1 was highly expressed in human ccRCC tumors and was associated with Vhl deficiency. Deletion of Cx3cl1 in cancer cells decreased myeloid cell infiltration associated with Vhl loss to provide a mechanism by which Vhl loss may have contributed to the altered immune landscape. Here, we identify cancer cell–specific genetic features that drove environmental reprogramming and shaped the tumor immune landscape, with therapeutic implications for the treatment of ccRCC.
- Open Access
- 8 August 2022
- Published by American Society for Clinical Investigation in JCI Insight
- Vol. 7 (15)
Ligand-independent integrin β1 signaling supports lung adenocarcinoma development
Integrins — the principal extracellular matrix (ECM) receptors of the cell — promote cell adhesion, migration, and proliferation, which are key events for cancer growth and metastasis. To date, most integrin-targeted cancer therapeutics have disrupted integrin-ECM interactions, which are viewed as critical for integrin functions. However, such agents have failed to improve cancer patient outcomes. We show that the highly expressed integrin β1 subunit is required for lung adenocarcinoma development in a carcinogen-induced mouse model. Likewise, human lung adenocarcinoma cell lines with integrin β1 deletion failed to form colonies in soft agar and tumors in mice. Mechanistically, we demonstrate that these effects do not require integrin β1–mediated adhesion to ECM but are dependent on integrin β1 cytoplasmic tail-mediated activation of focal adhesion kinase (FAK). These studies support a critical role for integrin β1 in lung tumorigenesis that is mediated through constitutive, ECM binding–independent signaling involving the cytoplasmic tail.
- 8 August 2022
- Published by American Society for Clinical Investigation in JCI Insight
- Vol. 7 (15)
Open AccessLigand-independent integrin β1 signaling supports lung adenocarcinoma development
Integrins — the principal extracellular matrix (ECM) receptors of the cell — promote cell adhesion, migration, and proliferation, which are key events for cancer growth and metastasis. To date, most integrin-targeted cancer therapeutics have disrupted integrin-ECM interactions, which are viewed as critical for integrin functions. However, such agents have failed to improve cancer patient outcomes. We show that the highly expressed integrin β1 subunit is required for lung adenocarcinoma development in a carcinogen-induced mouse model. Likewise, human lung adenocarcinoma cell lines with integrin β1 deletion failed to form colonies in soft agar and tumors in mice. Mechanistically, we demonstrate that these effects do not require integrin β1–mediated adhesion to ECM but are dependent on integrin β1 cytoplasmic tail-mediated activation of focal adhesion kinase (FAK). These studies support a critical role for integrin β1 in lung tumorigenesis that is mediated through constitutive, ECM binding–independent signaling involving the cytoplasmic tail.
- Top Cited Papers
Single-cell protein activity analysis identifies recurrence-associated renal tumor macrophages